Tags

Type your tag names separated by a space and hit enter

Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man.
Dig Dis Sci. 1993 Oct; 38(10):1889-92.DD

Abstract

Cholecystokinin (CCK) decreases lower esophageal sphincter pressure (LESP) in man. Cholestyramine, a nonabsorbable bile salt binding resin, stimulates endogenous CCK secretion. We have investigated the effect of oral ingestion of 16 g cholestyramine without and with infusion of the CCK receptor antagonist CR1505 (loxiglumide, 15 mg/kg/90 min) on LESP in seven healthy subjects. LESP was recorded for 90 min, in 10-min intervals, with the pull-through technique using a four-lumen water-perfused catheter. Oral ingestion of cholestyramine resulted in a significant (P < 0.05) decrease in LESP, starting from 10 min and continuing during the entire experiment (basal LESP: 11.8 +/- 2 mm Hg, minimal value reached during cholestyramine: 7.3 +/- 1 mm Hg; P < 0.05). Pretreatment with loxiglumide completely antagonized the effect of cholestyramine on LESP. Infusion of loxiglumide without cholestyramine did not affect basal LESP. It is concluded that: (1) cholestyramine significantly reduces LESP; (2) this reduction in LESP does not occur after pretreatment with loxiglumide, indicating that cholestyramine influences LESP through CCK release; and (3) basal LESP is not regulated by CCK.

Authors+Show Affiliations

Department of Gastroenterology-Hepatology, University Hospital Leiden, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8404410

Citation

Masclee, A A., et al. "Effect of Cholestyramine and Cholecystokinin Receptor Antagonist CR1505 (loxiglumide) On Lower Esophageal Sphincter Pressure in Man." Digestive Diseases and Sciences, vol. 38, no. 10, 1993, pp. 1889-92.
Masclee AA, Jansen JB, Rovati LC, et al. Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man. Dig Dis Sci. 1993;38(10):1889-92.
Masclee, A. A., Jansen, J. B., Rovati, L. C., & Lamers, C. B. (1993). Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man. Digestive Diseases and Sciences, 38(10), 1889-92.
Masclee AA, et al. Effect of Cholestyramine and Cholecystokinin Receptor Antagonist CR1505 (loxiglumide) On Lower Esophageal Sphincter Pressure in Man. Dig Dis Sci. 1993;38(10):1889-92. PubMed PMID: 8404410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man. AU - Masclee,A A, AU - Jansen,J B, AU - Rovati,L C, AU - Lamers,C B, PY - 1993/10/1/pubmed PY - 1993/10/1/medline PY - 1993/10/1/entrez SP - 1889 EP - 92 JF - Digestive diseases and sciences JO - Dig Dis Sci VL - 38 IS - 10 N2 - Cholecystokinin (CCK) decreases lower esophageal sphincter pressure (LESP) in man. Cholestyramine, a nonabsorbable bile salt binding resin, stimulates endogenous CCK secretion. We have investigated the effect of oral ingestion of 16 g cholestyramine without and with infusion of the CCK receptor antagonist CR1505 (loxiglumide, 15 mg/kg/90 min) on LESP in seven healthy subjects. LESP was recorded for 90 min, in 10-min intervals, with the pull-through technique using a four-lumen water-perfused catheter. Oral ingestion of cholestyramine resulted in a significant (P < 0.05) decrease in LESP, starting from 10 min and continuing during the entire experiment (basal LESP: 11.8 +/- 2 mm Hg, minimal value reached during cholestyramine: 7.3 +/- 1 mm Hg; P < 0.05). Pretreatment with loxiglumide completely antagonized the effect of cholestyramine on LESP. Infusion of loxiglumide without cholestyramine did not affect basal LESP. It is concluded that: (1) cholestyramine significantly reduces LESP; (2) this reduction in LESP does not occur after pretreatment with loxiglumide, indicating that cholestyramine influences LESP through CCK release; and (3) basal LESP is not regulated by CCK. SN - 0163-2116 UR - https://www.unboundmedicine.com/medline/citation/8404410/Effect_of_cholestyramine_and_cholecystokinin_receptor_antagonist_CR1505__loxiglumide__on_lower_esophageal_sphincter_pressure_in_man_ DB - PRIME DP - Unbound Medicine ER -